HK Stock Concept Tracker | 51 Class 1 innovative drugs included in the new national medical insurance drug list! Commercialization of innovative drugs accelerates (with concept stocks attached)
On November 14, at the 2026 Innovative Drug High-Quality Development Conference held in Suzhou, the adjustment results for the 2026 National Basic Medical Insurance Drug List and the Commercial Health Insurance Innovative Drug List were officially announced.
On November 14, at the 2026 Innovative Drugs High-Quality Development Conference held in Suzhou, the adjustment results for the 2026 National Basic Medical Insurance Drug List and the Commercial Health Insurance Innovative Drug List were officially announced. The basic medical insurance list newly included 107 drugs, of which 51 are Class 1 innovative drugs, a record high. The commercial insurance innovative drug list newly included 12 drugs, bringing the total to 28. Meanwhile, two drugs previously included in the commercial insurance innovative drug list were further incorporated into basic medical insurance this year, and CAR-T products achieved basic medical insurance access for the first time.
From this round of medical insurance list adjustment, multiple blockbuster innovative drugs achieved "approval and inclusion in the same year." The newly added drugs cover multiple clinical areas including oncology, rare diseases, chronic diseases, mental illness, and pediatric drugs, with priority given to innovative drugs with clear clinical benefits and favorable economic evaluations.
After the adjustment, the total number of drugs in the National Basic Medical Insurance Drug List reached 3,331, including 1,935 western medicines and 1,396 Chinese patent medicines.
Analysts noted that as innovative drugs continue to accelerate their entry into medical insurance, the industry's commercialization process is expected to further accelerate. The continuous improvement of the dynamic adjustment mechanism for the medical insurance list helps shorten the time from approval and launch to medical insurance inclusion for innovative drugs, improves patient access to medications, and is also expected to further drive commercialization volume growth for innovative drugs.
It is worth noting that with the implementation of the medical insurance list, policy support for innovative drugs is further extending from medical insurance access to in-hospital formulary inclusion and clinical use. Zhang Ke, Director of the National Healthcare Security Administration, stated that efforts will be made to promote "pre-admission" of new drugs in the list to hospitals, and "face-to-face" activities involving "medical institutions, pharmacies, insurance, and academia" will be carried out in 12 cities to promote innovative technologies and the latest achievements into hospitals, pharmacies, prescriptions, and classrooms.
Meanwhile, the National Health Commission, the National Healthcare Security Administration, the National Administration of Traditional Chinese Medicine, and the National Disease Control and Prevention Administration recently jointly issued a notice to further ensure the safe and rational formulary inclusion and use of innovative drugs. The notice requires medical institutions at or above the second level to optimize the hospital admission process for innovative drugs and promptly include them in medication formularies based on diagnostic and treatment needs. Class 1 new drugs in both lists are not counted toward the "one product, two specifications" rule and are not included in performance monitoring indicators such as the growth rate of average outpatient and inpatient drug costs. For cases involving innovative drugs in the medical insurance list that are not suitable for payment under disease-based payment standards, special case single-case review can be applied for, which helps further smooth the clinical use and payment channels for innovative drugs.
From an industry trend perspective, the innovative drug sector is gradually entering a development stage that emphasizes both "R&D innovation + commercialization realization." As the linkage mechanism between the medical insurance and commercial insurance "dual lists" is gradually established, and the hospital admission and clinical use processes for innovative drugs continue to be optimized, pharmaceutical companies with strong innovation capabilities, outstanding commercialization capabilities, and blockbuster products successively entering their volume growth phase are expected to benefit first.
CITIC SEC issued a research report noting that national medical insurance negotiations continue to support innovative drugs, with attention on 2027 commercialization increments. As access and renewal rules are further improved, long-term commercialization expectations for innovative drugs are becoming clearer. At the same time, hospital admission and payment support are advancing in tandem, which is expected to accelerate the conversion of list access into prescription volume growth. The firm believes that CAR-T entering basic medical insurance for the first time is expected to improve accessibility of cell therapy, and the expansion of ADC medical insurance payment scope to more advanced treatment lines and more cancer types is expected to drive domestic sales growth.
Sinolink issued a research report noting that the dual lists broaden patient payment coverage, and hospital admission policies are expected to accelerate the conversion of list access into in-hospital prescriptions. It is bullish on domestic innovative drug in-hospital volume growth in 2027, with focus on nationally negotiated new products with clear clinical demand and room for further hospital coverage improvement, as well as commercial insurance coverage and actual reimbursement progress for high-value therapies.
Related concept stocks
INNOVENT BIO (01801): According to the company's announcement, seven of its innovative products were successfully included in the 2026 National Medical Insurance Drug List, covering disease areas with heavy social burden such as oncology (colorectal cancer, renal cancer, hematological tumors), cardiovascular and metabolic diseases, and autoimmune diseases. These include products included in medical insurance for the first time such as mazdutide, picankibart, and ipilimumab N01, as well as products with newly added indications included in medical insurance such as sintilimab and pirtobrutinib. As of this adjustment, the company's innovative drug portfolio included in the National Medical Insurance Drug List has expanded to 17 products.
SUNSHINE PHARMA (06887): The company's independently developed sodium-glucose transport protein 2 inhibitor (SGLT-2 inhibitor), Class 1 innovative drug Ologlitazin Capsules (trade name: Dongze'an), was successfully included in the 2026 National Medical Insurance Drug List. The product was approved for marketing in January 2026 and can be used as monotherapy or in combination with metformin to improve glycemic control in adult patients with type 2 diabetes, achieving "approval and inclusion in the same year" in the medical insurance list.
HENLIUS (02696): The company's Hansizhuang (serplulimab injection) was included in the 2026 National Medical Insurance Drug List for the first time, covering all indications approved for marketing in China; the second indication of Futoning (voruciclib citrate capsules) was newly added to the National Medical Insurance Drug List.
JW THERAP-B (02126): The company's core product Beinuoda (relma-cel injection) was officially included in the 2026 National Basic Medical Insurance Drug List, covering three indications: large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. It is worth noting that Beinuoda is the only CAR-T therapy product included in the National Basic Medical Insurance Drug List this time, marking an important breakthrough in achieving basic medical insurance access for CAR-T.
Related Articles

CICC: Maintains YUE YUEN IND (00551) target price at HK$15.64, maintains "Outperform" rating.

ENVISION GREEN (01783) signs another locked-card agreement, strengthening its compliant rental calculation logic.

Guotai Haitong: AI Moves Toward the Physical World, Data Services Usher in New Opportunities
CICC: Maintains YUE YUEN IND (00551) target price at HK$15.64, maintains "Outperform" rating.

ENVISION GREEN (01783) signs another locked-card agreement, strengthening its compliant rental calculation logic.

Guotai Haitong: AI Moves Toward the Physical World, Data Services Usher in New Opportunities






